

UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION

Page 1 of 2

PATENT NO. : 7,592,150  
APPLICATION NO. : 10/728,227  
ISSUE DATE : September 22, 2009  
INVENTOR(S) : Nir Dotan et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 27, Line 12, Claim 10, "can antibody in said sample is an IgG isotype antibody," should read -- can antibody in said sample is an IgG isotype antibody. --

Column 27, Lines 25-26, Claim 12, "as having Crohn's disease if said ALCA and said polysaccharide ( $\beta$  1-3) Glucan antibody levels are elevated in said," should read -- as having Crohn's disease if said ALCA and said polysaccharide  $\beta$ -D (1-3) Glucan antibody levels are elevated in said --

Column 27, Line 62, Claim 18, "( $\alpha$  1-3) [Man ( $\alpha$  1-6)] Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-2)," should read -- ( $\alpha$  1-3) Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-3)[Man ( $\alpha$  1-6)] Man ( $\alpha$ ) antibody, anti-Man ( $\alpha$  1-2) --

Column 29, Line 4, Claim 35, "detected with an enzyme-linked inununoabsorbent assay," should read -- detected with an enzyme-linked immunoabsorbent assay --

Column 29, Line 11, Claim 37, "GlcNAc ( $\beta$ ) antibody (ACCA) or an anti-polysaccharide  $\beta$ -D," should read -- GlcNAc ( $\beta$ ) antibody (ACCA) or an anti-polysaccharide  $\beta$ -D --

Column 29, Line 14, Claim 37, "anti-polysaccharide  $\beta$ -D (1-3) Glucan antibody levels are," should be -- anti-polysaccharide  $\beta$ -D (1-3) Glucan antibody levels are --

Column 29, Lines 36-37, Claim 42, "comprises detecting a level of an anti-GlcNAc ( $\beta$  1-4) GlcNAc ( $\beta$ ) antibody (ACCA) and an anti-polysaccharide," should be -- comprises detecting a level of an anti-GlcNAc ( $\beta$  1-4) GlcNAc ( $\beta$ ) antibody (ACCA) and an anti-polysaccharide --

MAILING ADDRESS OF SENDER (Please do not use customer number below):  
Ingrid A. Beattie  
MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111

**UNITED STATES PATENT AND TRADEMARK OFFICE  
CERTIFICATE OF CORRECTION**

Page 2 of 2

PATENT NO. : 7,592,150  
APPLICATION NO. : 10/728,227  
ISSUE DATE : September 22, 2009  
INVENTOR(S) : Nir Dotan et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

Column 30, Line 29, Claim 50, "IgG ALCA, IgC ASCA, or IgA ASCA antibodies are"  
should read -- IgG ALCA, IgG ASCA, or IgA ASCA antibodies are --

Column 30, Line 57, Claim 53, "GlcNAc ( $\beta$ ) glycan, said Glc( $\beta$  1-3) Glc ( $\beta$ ) , said  
mannan, and" should read -- GlcNAc ( $\beta$ ) , said Glc( $\beta$  1-3) Glc ( $\beta$ ) , said mannan, and --

MAILING ADDRESS OF SENDER (Please do not use customer number below):  
Ingrid A. Beattie  
MINTZ LEVIN COHN FERRIS GLOVSKY AND POPEO, P.C.  
One Financial Center  
Boston, Massachusetts 02111